Congress quietly exempts premium cigars from FDA oversight

What it does

This bill amends federal tobacco law to exempt 'premium cigars' from FDA regulation by redefining them as non-tobacco products under the Federal Food, Drug, and Cosmetic Act. Premium cigars are defined narrowly as hand-rolled, all-leaf products weighing over 6 pounds per 1,000 units, sold primarily through specialty retailers. The bill cites a 2022 National Academies study finding that premium cigars are used by only 1% of adults, rarely by youth, and pose lower health risks than other tobacco products.

Why we flagged it

The bill's core function is to carve out a specific tobacco product category from federal regulatory oversight, benefiting premium cigar manufacturers and retailers by exempting them from FDA rules that apply to all other tobacco products.

What the text implies

• Exemption may create regulatory arbitrage: manufacturers could reclassify products to meet the narrow 'premium cigar' definition to escape FDA oversight, potentially undermining the intent of the exemption.
• The bill relies on a single 2022 National Academies report and a district court ruling (Judge Mehta's decision) to justify exemption, but does not address whether FDA has appealed or whether the court's reasoning applies to all premium cigars or only a subset.
• Exemption removes ingredient disclosure and marketing restrictions, meaning premium cigars could be marketed without the same warnings, age-gating, or advertising limits applied to other tobacco products, creating a two-tier regulatory system.
• State-level regulation (mentioned in findings) may be inconsistent and fragmented, leaving gaps in consumer protection and creating compliance complexity for multi-state retailers.

Who it affects

Ordinary citizens lose FDA oversight of a tobacco product category, reducing consumer protections and regulatory transparency. While the bill frames premium cigars as low-risk, exempting them from federal regulation removes safety monitoring, ingredient disclosure, and marketing restrictions that apply to other tobacco products—a regulatory carve-out that prioritizes industry interests over public health consistency.

Who stands to gain

• premium cigar manufacturers
• specialty tobacco retailers
• cigar bar operators

Named in the bill

FDA (Food and Drug Administration), National Academies of Sciences, Engineering, and Medicine (NASEM), Judge Amit P. Mehta, U.S. District Court for the District of Columbia, Federal Food, Drug, and Cosmetic Act, House Committee on Energy and Commerce

Where it stands

16 cosponsors: 9 Democrats, 7 Republicans.

• Mar 14, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 14, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 13 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,268,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Byron Donalds, the sponsor, reported $66,946 in PAC receipts in the 2026 cycle.

• Tobacco-free Kids Action Fund — $874,000 on 3 filings
• Cigar Rights of America — $144,000 on 2 filings
• Cigar Rights of America — $100,000 on 2 filings
• Campaign for Tobacco-free Kids — $70,000 on 2 filings
• Tobacco-free Kids Action Fund — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.